Sotio
SOTIO Biotech is a Czech biotechnology company focused on clinical-stage research and development of innovative medicines for cancer with operations in Europe, North America, and Asia. The company has clinical programs which include a superagonist of the immuno-oncology target IL-15, a new generation of potent and stable antibody-drug conjugates (ADCs), proprietary technology designed to improve on the efficacy of CAR T therapies and a platform to streamline and enhance personalized cell therapies.
| Industry | Biotechnology, Pharmaceutical |
|---|---|
| Founded | 2010 |
| Founder | Petr Kellner |
| Headquarters | , |
Key people | Radek Spisek, Ph.D., CEO |
| Revenue | 176,068,000 Czech koruna (2021) |
| −319,386,000 Czech koruna (2021) | |
| −344,344,000 Czech koruna (2021) | |
| Total assets | 6,689,850,000 Czech koruna (2021) |
Number of employees | 200 |
| Website | https://www.sotio.com/ |
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.